Inactive

Background: The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which... Background: The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: February 2020: The following drug classes/subclass and newly approved agents will be reviewed: Acne Agents, SUB CLASS: Topical Acne and Rosacea - Aklief Pulmonary 1-Agents, SUB CLASS: Pulmonary Miscellaneous - Fasenra Antigout Agents, SUB CLASS: Acute - Gloperba Skeletal Muscle Relaxants and Combinations, SUB CLASS: NA - Ozobax Pulmonary – 1 Agents, SUB CLASS: Short Acting Beta Agonists – Proair Digihaler Cystic Fibrosis Agents, SUB CLASS: NA – Trikafta Multiple Sclerosis Agents, SUB CLASS: Methy Fumarate – Vumerity RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein.There is no pre-proposal teleconference for Newly Approved Drugs RFQ. Questions shall besubmitted via e-mail to the RFQ Point of Contact stated in Part 2.3, no later than the date stated in Part 2.4. Also, responses to Part 3.4 is required. POCs: Part 2.3 of the RFQ. For additional information, search DoD Pharmacy and Therapeutics (P&T)Committee at http://www.health.mil/POD